It has been reported that lateral ventricle injection of STZ could induce AD-like behavior in rats [32] or mice [33–37], as indicated by significant cognitive impairment and increased Aβ1-42 accumulation and hyperphosphorylated tau in the hippocampus [32], along with increased glial activation or decreased expression of synapse-associated protein [33–37]. This evidence concerns the gene MAPT and Alzheimer disease.